IL288568A - Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors - Google Patents

Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors

Info

Publication number
IL288568A
IL288568A IL288568A IL28856821A IL288568A IL 288568 A IL288568 A IL 288568A IL 288568 A IL288568 A IL 288568A IL 28856821 A IL28856821 A IL 28856821A IL 288568 A IL288568 A IL 288568A
Authority
IL
Israel
Prior art keywords
amino
methylpyrazin
decan
azaspiro
chloropyridin
Prior art date
Application number
IL288568A
Other languages
English (en)
Hebrew (he)
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of IL288568A publication Critical patent/IL288568A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL288568A 2019-06-07 2021-12-01 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors IL288568A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07
PCT/US2020/036137 WO2020247643A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Publications (1)

Publication Number Publication Date
IL288568A true IL288568A (en) 2022-02-01

Family

ID=71787182

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288568A IL288568A (en) 2019-06-07 2021-12-01 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors

Country Status (15)

Country Link
US (2) US11220501B2 (https=)
EP (1) EP3980128A1 (https=)
JP (2) JP2022534788A (https=)
KR (1) KR20220019017A (https=)
CN (2) CN115141205A (https=)
AU (1) AU2020288631A1 (https=)
BR (1) BR112021022635A2 (https=)
CA (1) CA3142430A1 (https=)
IL (1) IL288568A (https=)
MA (1) MA56113A (https=)
MX (1) MX2021014855A (https=)
PH (1) PH12021552902A1 (https=)
SG (1) SG11202112461QA (https=)
TW (1) TW202112785A (https=)
WO (1) WO2020247643A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
EP3980128A1 (en) 2019-06-07 2022-04-13 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
CA2606288A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
KR101906146B1 (ko) * 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6523303B2 (ja) * 2014-01-17 2019-05-29 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
KR102598895B1 (ko) * 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
SG11202009793TA (en) 2018-04-10 2020-10-29 Revolution Medicines Inc Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
EP3980128A1 (en) * 2019-06-07 2022-04-13 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Also Published As

Publication number Publication date
WO2020247643A1 (en) 2020-12-10
JP2025138706A (ja) 2025-09-25
SG11202112461QA (en) 2021-12-30
AU2020288631A1 (en) 2021-12-09
BR112021022635A2 (pt) 2022-01-04
CA3142430A1 (en) 2020-12-10
MX2021014855A (es) 2022-01-18
US12528807B2 (en) 2026-01-20
EP3980128A1 (en) 2022-04-13
MA56113A (fr) 2022-04-13
PH12021552902A1 (en) 2022-04-04
US11220501B2 (en) 2022-01-11
CN115141205A (zh) 2022-10-04
JP2022534788A (ja) 2022-08-03
US20220298159A1 (en) 2022-09-22
KR20220019017A (ko) 2022-02-15
TW202112785A (zh) 2021-04-01
US20210253574A1 (en) 2021-08-19
CN114190090A (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
IL288568A (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,s4)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5] Decan-8-yl]-5-methylpyrazin-2-yl}methanol as shp2 inhibitors
CA3294689A1 (en) Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
IL288236A (en) 3,2-dihydroquinazoline compounds as inhibitors of nav1.8
EP3983433A4 (en) NOVEL INTERLEUKIN-2 VARIANTS FOR CANCER TREATMENT
EP3841204A4 (en) CHANGED TARGET SPECIFIC BASE EDITORS
WO2021022163A3 (en) Compounds and uses thereof
EP3774166A4 (en) LASER PROCESSING DEVICE, METHOD OF OPERATION THEREOF AND METHOD OF PROCESSING WORKPIECES USING SAME
WO2018100233A3 (en) Distributed audio capture and mixing controlling
MX2020002033A (es) Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.
WO2021138046A8 (en) Strap-segment-cutting system
EP3493206A3 (en) Electronic apparatus and control method thereof
EP3867324A4 (en) TWO-PART CYANOACRYLATE/FREE-ADICAL BONDING SYSTEMS
IL320582A (en) Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
EP4046064A4 (en) SYSTEMS AND METHODS FOR TRACKING GAMING CHIPS
EP4062934A4 (en) COMPOSITION FOR PREVENTING OR TREATING CANCER WITH ANTI-CD300C MONOCLONAL ANTIBODIES
HK40072890A (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
EP3789449A3 (en) Polyester having a reduced level of acetaldehyde
MX2021008009A (es) Inhibidores del receptor de crecimiento transformante beta 1 (alk5) para tratar el sindrome mielodisplasico.
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
EP4079433A4 (en) POINTED SAW
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof
EP4076460A4 (en) PRMT5 INHIBITORS
EP3975113A4 (en) INFORMATION PROCESSING DEVICE
EP4078122A4 (en) SEMICONDUCTOR METAL-OXIDE FIELD EFFECT TRANSISTOR OVERHEATING DETECTION
EP4649947A3 (en) Methods for treating against viruses